SYBX חוב כולל להון Synlogic

Synlogic, Inc. (SYBX) management is currently focusing on optimizing liquidation value and maintaining transparency with investors following a strategic pivot. This price chart confirms this direction, capturing the total debt-to-equity ratio at 0.00. The business relies on the development of synthetic biologics in US laboratories, utilizing the genetic modification of probiotics. However, competitive advantages have been lost due to the freezing of core programs, leaving the company with only cash reserves.

The market assesses Synlogic, Inc. (SYBX) as an entity in the liquidation stage, where a lack of operating leverage leaves the company vulnerable to fixed costs. By analyzing the debt-to-equity ratio, an investor determines the proportion of borrowed funds used to finance assets; an increase in this ratio on the chart signals critical equity dilution and a high risk of insolvency when settling obligations.